Seeking Alpha

Endo Health (ENDP) says the U.S. District Court has ruled against its bid to stop sales of...

Endo Health (ENDP) says the U.S. District Court has ruled against its bid to stop sales of generic versions of its painkiller Opana ER, saying the FDA has not unduly delayed making a determination on the matter as to whether the original formulation was withdrawn from the market for reasons of safety. The ruling now allows for a generic non-tamper resistant version to enter the market in January, 2013. Shares -3.6% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)